OncoCyte Price To Sales Ratio from 2010 to 2025
| OCX Stock | USD 2.58 0.06 2.38% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 14.64 | Current Value 13.9 | Quarterly Volatility 51.9908069 |
Check OncoCyte Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OncoCyte Corp's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 56.8 K or Selling General Administrative of 11.2 M, as well as many indicators such as Price To Sales Ratio of 13.9, Dividend Yield of 0.0015 or PTB Ratio of 0.64. OncoCyte financial statements analysis is a perfect complement when working with OncoCyte Corp Valuation or Volatility modules.
OncoCyte | Price To Sales Ratio |
Latest OncoCyte Corp's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of OncoCyte Corp over the last few years. Price to Sales Ratio is figured by comparing OncoCyte Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on OncoCyte Corp sales, a figure that is much harder to manipulate than other OncoCyte Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. OncoCyte Corp's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OncoCyte Corp's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 101.65 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
OncoCyte Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 94.94 | |
| Geometric Mean | 70.65 | |
| Coefficient Of Variation | 54.76 | |
| Mean Deviation | 46.42 | |
| Median | 128.69 | |
| Standard Deviation | 51.99 | |
| Sample Variance | 2,703 | |
| Range | 116 | |
| R-Value | (0.81) | |
| Mean Square Error | 986.12 | |
| R-Squared | 0.66 | |
| Significance | 0.0001 | |
| Slope | (8.87) | |
| Total Sum of Squares | 40,546 |
OncoCyte Price To Sales Ratio History
About OncoCyte Corp Financial Statements
OncoCyte Corp investors use historical fundamental indicators, such as OncoCyte Corp's Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in OncoCyte Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 14.64 | 13.90 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.